- Home
- KAVL vs EDSA Comparison
KAVL vs EDSA Comparison
Compare KAVL & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- EDSA
- Stock Information
- Founded
- KAVL 1998
- EDSA 2015
- Country
- KAVL United States
- EDSA Canada
- Employees
- KAVL N/A
- EDSA 16
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- EDSA Health Care
- Exchange
- KAVL Nasdaq
- EDSA Nasdaq
- Market Cap
- KAVL 6.2M
- EDSA 6.0M
- IPO Year
- KAVL N/A
- EDSA N/A
- Fundamental
- Price
- KAVL $0.80
- EDSA $1.85
- Analyst Decision
- KAVL
- EDSA Strong Buy
- Analyst Count
- KAVL 0
- EDSA 1
- Target Price
- KAVL N/A
- EDSA $21.00
- AVG Volume (30 Days)
- KAVL 143.2K
- EDSA 30.8K
- Earning Date
- KAVL 02-13-2025
- EDSA 02-07-2025
- Dividend Yield
- KAVL N/A
- EDSA N/A
- EPS Growth
- KAVL N/A
- EDSA N/A
- EPS
- KAVL N/A
- EDSA N/A
- Revenue
- KAVL $10,108,906.00
- EDSA N/A
- Revenue This Year
- KAVL $652.90
- EDSA N/A
- Revenue Next Year
- KAVL N/A
- EDSA N/A
- P/E Ratio
- KAVL N/A
- EDSA N/A
- Revenue Growth
- KAVL N/A
- EDSA N/A
- 52 Week Low
- KAVL $0.58
- EDSA $1.55
- 52 Week High
- KAVL $9.69
- EDSA $5.99
- Technical
- Relative Strength Index (RSI)
- KAVL 50.73
- EDSA 31.51
- Support Level
- KAVL $0.78
- EDSA $1.73
- Resistance Level
- KAVL $0.91
- EDSA $1.99
- Average True Range (ATR)
- KAVL 0.07
- EDSA 0.19
- MACD
- KAVL 0.01
- EDSA 0.02
- Stochastic Oscillator
- KAVL 65.22
- EDSA 18.00
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.